• Four Tubeless Pumps in 2027?! CGM studies in older people, new T1D insurance tool, ADA controversy continues, and more!
    Nov 17 2026
    This week on Diabetes Connections In the News… two new tubeless pumps are cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns.. Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Transcript: This week on Diabetes Connections In the News… a new tubeless pump is cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns.. It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. We've got a lot to get to, so let's just dive in! Our top story this week: XX Big news – there are now FOUR tubeless insulin pumps FDA cleared. MiniMed Fit and tandem mobi tubeless cleared in the past week – add those to the Beta Bionics Mint and of course, the original, Omnipod. Just yesterday, the FDA cleared the new MiniMed Fit system, which can be worn for up to seven days and holds 300 units of insulin. It has a reusable pump core and a Disposable cartridge – the cannula is built in, so no separate infusion set. Holds 300 units of insulin, with a built-in cannula and reliable adhesive for up to 7 day wear. Reusable pump core — The brains of the pump, this rechargeable part attaches to the disposable cartridge. One charge lasts up to 7 days.The pump uses the same SmartGuard automated insulin delivery technology as MiniMed Flex, adjusting insulin and making corrections every five minutes. The system is fully controlled by smartphone and will be available through pharmacies, with a phased U.S. rollout planned for 2027. https://news.minimed.com/2026-11-16-FDA-Clears-MiniMed-Fit-TM-Worlds-First-and-Only-Tubeless-Insulin-Pump-with-Up-to-Seven-Day-Wear-and-Zero-Interruptions XX Just a few days ago, Tandem Diabetes Care received clearance clearance for a tubeless version of its Mobi insulin pump, with a wearable cartridge and infusion set designed to last up to seven days. Tandem plans a full U.S. launch in the first half of 2027, with distribution exclusively through pharmacies. This gives people with type 1 another potential option for automated insulin delivery without traditional pump tubing. https://www.drugdeliverybusiness.com/tandems-mobi-pump-wins-fda-clearance-for-7-day-tubeless-wearable-set/ In other Tandem news, the company has issued a recall-related correction affecting more than 80,000 Mobi insulin pumps because of a problem that can trigger false occlusion alarms and interrupt insulin delivery. As of late October, Tandem had received reports of 230 adverse events requiring medical attention or hospitalization, although no deaths had been reported. The issue involves friction inside the pump's motor mechanism, which can cause the device to mistakenly detect a blockage. Tandem says customers can continue using their pumps but should respond promptly to alarms, keep a backup insulin delivery method available, and contact customer support if alarms repeatedly interrupt therapy. The company is investigating the problem and working to prevent it in future devices. https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pump-reports-230-adverse-events/874386/ XX Just in time for open enrollment, a new free tool aims to make choosing health insurance a little less overwhelming for people with diabetes. The GlucoSense Insurance Navigator compares 2027 Marketplace plans based on what you'll actually spend over the course of a year, not just your monthly premium. It factors in deductibles, insulin, CGMs, pump supplies, doctor visits, and even manufacturer savings cards to estimate your total annual costs. The tool's developers say early users have identified plans that could save them thousands of dollars a year. It's available through the GlucoSense app, although you'll still want to confirm...
    Show More Show Less
    14 mins
  • Finding Diabetes Joy: How Poetry Helped Ephraim Navigate a T1D Diagnosis
    Nov 13 2026

    In this bonus episode of Diabetes Connections, meet Ephraim Sommers, an English professor and poet diagnosed with LADA (a slower-developing form of type 1 diabetes) in his early 40s.

    Even though his father has type 1, Ephraim wasn't prepared for the fear, anxiety, and mental load of managing diabetes himself.

    So he turned to poetry. Every weekday, he sat in a coffee shop and wrote about gratitude. Those poems became Diabetic Gumdrops, a new book about finding joy while living with diabetes.

    We talk about shifting from fear to gratitude, advocating for yourself, and why poetry might help even if you haven't read a poem since high school.

    Plus, Ephraim lives right here in the Charlotte area! We had a great time talking about the local T1D community and how important connection can be.

    Check out all of our events like Moms' Night Out and Club 1921 here.

    Announcing Community Commericals! Learn how to get your message on the show here.


    Learn more about studies and research at Thrivable here


    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Show More Show Less
    25 mins
  • Can a 100-Old Vaccine Impact Type 1 Diabetes? A Conversation with Dr. Denise Faustman
    Nov 10 2026

    This week on Diabetes Connections - looking into a very old vaccine to get new results for people with type 1. Dr. Denise Faustman's research into the BCG vaccine has been making headlines for a long time, and she's now sharing new results from her clinical trials, including some pretty remarkable claims about A1C, insulin use, and time in range.

    Now, I know some of you may be surprised that I'm having Dr. Faustman on the show. She's a very controversial figure in the diabetes research world, and her work has sparked plenty of debate and skepticism over the years.

    We're not ignoring any of that. In fact, we talk directly about the controversy, why she believes her research has faced resistance, and what it would take for BCG to become a widely accepted treatment.

    This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

    More about Dr. Faustman's work here

    More about the controversy and history here

    Check out all of our events like Moms' Night Out and Club 1921 here.

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Show More Show Less
    39 mins
  • In the News... CGM Coverage, Why A1C vs GMI Matters, Fully Implantable CGM Trialed, T1D at the NYC Marathon and more
    Nov 3 2026
    This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for sports on the highest level with type 1. And it's diabetes awareness momth! It's all coming up right after this. (AD BREAK) Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Diabetes Awareness Month – I've got some news there, but there are SO many campaigns and releases this month. I've always said it's always diabetes awareness month around here and these awareness campaigns are for the engeral ppulario. So I'm sure you're inundated – I'll highlight what I think it noteworthy. We're in Phoenix this week for our last in person event of the year. This is a Club 1921 event for the whole community. We will have more of these next year – but our Next in person event will be Tampa in March for MNO – that's open and we have a flash sale until the end of this month. Okay.. our top story this week: XX Some people with diabetes may have to switch continuous glucose monitors starting January 1, 2027, because of insurance coverage changes involving CVS Caremark and Aetna. According to the Diabetes Patient Advocacy Coalition, some plans are moving to exclusive contracts that favor Abbott's FreeStyle Libre over Dexcom. Not everyone will be affected, and some patients may still be able to get their preferred CGM covered through medical rather than pharmacy benefits. DPAC is pushing back, arguing that insurance contracts shouldn't force people to change diabetes technology that's working for them. The organization is encouraging people to contact CVS Caremark and Aetna leadership through its online advocacy campaign. https://diabetespatientadvocacycoalition.quorum.us/campaign/cgmcvs XX Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app. Statement from Dexcom: We understand the concerns surrounding our roll out of our Terms of Use and Privacy Notice and recognize the importance of providing users with clear information. These updates are intended to support the continued operation, security and innovation of our products, while providing greater transparency into how data may be collected and used. We take our responsibility to protect users' personal information seriously and remain committed to handling their data responsibly. Like many digital services, continued use of the Dexcom app requires acceptance of the updated Terms of Use. Moving forward, users will have 30 days from acceptance to opt out of the arbitration provisions and may also opt out of certain cookies and data-sharing activities at any time. We understand the importance of uninterrupted access to glucose data for people managing diabetes. We are reviewing how we communicate and implement changes like these in the future to ensure users have the information they need and a clear understanding of their choices. XX Senseonics announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without the need for an external on-body transmitter. Unlike the current Eversense, which uses a removable transmitter worn over the implanted sensor, Freedom is designed to communicate directly with a smartphone using Bluetooth. The initial study will focus on safety, design, and wireless communication. Senseonics hopes to begin a larger clinical trial in 2027, with a possible commercial launch in 2028 if development and regulatory review go as planned. Source: Drug Delivery Business News XX In patients with type 1 diabetes (T1D), having a laboratory A1c higher than the glucose management indicator (GMI), your CGM, was associated with more microvascular complications. Researchers in Spain studied more than 1,300 adults with type 1 diabetes and found that people whose laboratory A1C was significantly higher than their CGM estimate were more likely to have complications involving their eyes, kidneys, or nerves. Those with the largest discrepancies had nearly twice the odds of these complications, even after researchers accounted for other clinical and CGM measurements. The study doesn't establish that the mismatch causes complications, but researchers say looking at both numbers together may help doctors better assess individual risk. Source: Medscape XX New research ...
    Show More Show Less
    13 mins
  • What We Learned at the Very First Breakthrough T1D Clinical & Research Congress, with Anastasia Albanese-O'Neill
    Oct 27 2026

    What happened at the very first Breakthrough T1D Clinical and Research Congress? More than a thousand people from 33 countries came together to talk about everything from islet cell transplants and new treatments to screening, prevention, and the growing role of GLP-1 medications in type 1 diabetes.

    I'm talking to Anastasia Albanese-O'Neill, vice president, medical affairs for Breakthrough, who joins us fresh off the conference to share the biggest headlines, what she's most excited about, and why she says we're at an inflection point in type 1 diabetes care.

    We also talk about how even the most promising breakthrough won't make a difference unless people can actually access it.

    This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

    More about the Congress here

    Check out all of our events like Moms' Night Out and Club 1921 here.

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Show More Show Less
    32 mins
  • Meet GLUKI, the T1D App Helping Kids Learn Through Play
    Oct 23 2026

    On this bonus episode of diabetes connections.. the creator of Gluki, a new app designed to help kids understand diabetes through games, rewards, and interactive learning.

    I'm talking to Staci DePatie who lives with type 1. Staci's working with students at UC Irvine to bring Gluki to life, including some interesting new AI features. We'll talk about how it all works, why she believes building what she calls "diabetes IQ" is so important, and I'll ask some questions about AI safety, cost, and whether kids really want to spend more time thinking about diabetes, even if it's as part of a game.

    This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

    Check out all of our events like Moms' Night Out and Club 1921 here.

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Show More Show Less
    28 mins
  • In the News.. Dexcom controversy, New T1D research, and a World Series moment to remember!
    Oct 20 2026
    This week on Diabetes Connections In the News… a change from Dexcom sparks a big community response New developments in the race to protect insulin-producing beta cells, Lilly's GLP-1 pill moves closer to approval in Europe, and could remote monitoring help kids with type 1 improve their glucose management? Plus, are pregnant women being left behind by automated insulin delivery technology? And a Major League moment to remember as a player with type 1 diabetes sends the Milwaukee Brewers to the World Series! Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Transcript: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Who else is getting ready for 2027? I know, I can't believe it either but I'm already booking to speak and we've got events on the books. I will not wish the rest of this year away, we've still got a lot going on, but please follow along, I'll keep you posted on where we're going and what's up. Off to Seattle in a couple of days for MNO.. Okay.. our top story this week: XX Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app. The notification included the message, "Please uninstall app if you don't agree." Some users reported they couldn't get past the notification to view their glucose readings without accepting the terms. The controversy centers on provisions involving mandatory arbitration and class action waivers. Those provisions can limit a user's ability to pursue certain legal claims against Dexcom in court, instead requiring disputes to be handled through individual arbitration. The updated terms also raise questions about data privacy and the use of information for artificial intelligence features. Rob howe from Diabetics Doing Things has an itnerivew going live later this week with Peter Simpson, CTO of Dexcom. Rob released a short clip from that interview, and gave me permission to re-air part of it here.. (clip) I have not yet confirmed with Dexcom, but others on social media say that Dexcom has since clarified that users can opt out of the arbitration provision and continue using the app. According to the terms shared by users, they have 30 days after accepting to opt out by emailing Dexcom's legal department with their name, address, and a statement declining arbitration. I've reached out to Dexcom, but have not yet received a response, they say they are working on it. If we get it after this episode goes live, I'll jump on social with an update. XX Immunocore has announced that the first person with type 1 diabetes has received an experimental treatment in a Phase 1 clinical trial. The therapy, called IMC-S118AI, is designed to protect insulin-producing beta cells by targeting and switching off the immune cells that attack them in people with T1D. Unlike treatments that affect the entire immune system, this approach is designed to work specifically around the beta cells, with the goal of preserving the body's ability to produce insulin. Earlier laboratory research using human pancreatic tissue showed promising results, including reduced immune attacks on beta cells and preserved insulin secretion. The Phase 1 trial will now evaluate the treatment's safety, how it moves through the body, and whether it shows signs of working in people with T1D who have a specific genetic marker. XX SAB Biotherapeutics has received FDA Fast Track designation for SAB-142, an experimental immune therapy designed to slow the progression of type 1 diabetes in people who have recently been diagnosed. The treatment uses human antibodies produced through genetically engineered cattle, with the goal of protecting the body's insulin-producing cells from immune system attacks. SAB-142 is currently being studied in a Phase 2b clinical trial involving people within 100 days of a Stage 3 type 1 diabetes diagnosis, with results expected in the second half of 2027. A separate Phase 3 study is also evaluating the treatment in people diagnosed between 100 days and two years earlier. Fast Track designation could help speed the development and...
    Show More Show Less
    20 mins
  • Sernova + Seraxis: A New Partnership in the Race for a T1D Cure with CEOs Johnathan Rigby and Dr. Will Rust
    Oct 13 2026

    A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes.

    So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1?

    I'm talking with the CEOs of the companies that are merging: Jonathan Rigby – who lives with type 1 - and Will Rust about the science, the challenges, and why they believe this combination could be a game changer.

    Our past episodes with Sernova here

    This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.

    Check out all of our events like Moms' Night Out and Club 1921 here.

    Announcing Community Commericals! Learn how to get your message on the show here.
    Learn more about studies and research at Thrivable here
    Please visit our Sponsors & Partners - they help make the show possible!
    Omnipod - Simplify Life
    All about Dexcom
    All about VIVI Cap to protect your insulin from extreme temperatures

    The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
    Sign up for our newsletter here

    Here's where to find us:
    Facebook (Group)
    Facebook (Page)
    Instagram
    Check out Stacey's books!

    Learn more about everything at our home page www.diabetes-connections.com

    Show More Show Less
    40 mins